1.Expressions and significances of RUNX3 and CyclinD1 in pancreatic carcinoma
Zhichuan LIN ; Jianguo LI ; Chunnuan WU ; Hongwu SHEN ; Zongkai ZOU
Chinese Journal of Pancreatology 2011;11(4):272-274
Objective To investigate the expressions of RUNX3 and CyclinDl in pancreatic carcinoma and their significance. Methods Expressions of RUNX3, CyclinD1 in 47 cases with pancreatic carcinoma, 18 cases with cystadenoma of pancreas and 12 normal pancreas cases were detected by immunohistochemistry, and the relationship between their expressions and clinicopathological parameters was analyzed. Results The positive expression rates of RUNX3 in pancreatic carcinoma, cystadenoma of pancreas, normal pancreas cases were 57.4% (27/47), 94.4% (17/18), 100% (12/12); the positive expression rates of CyclinD1 in pancreatic carcinoma, cystadenoma of pancreas, normal pancreas cases were 72.3% (34/47), 44.4%(8/18), 8.3% (1/12). RUNX3 expression was not related to the age and sex, but it was negatively associated with clinical staging, lymph node metastasis, the differentiation degree (P <0.05 ). CyclinD1 expression was not related to the age and sex, but it was positively associated with clinical staging, lymph node metastasis, the differentiation degree (P <0.05 ). The expression of RUNX3 and CyclinD1 was negatively associated (r = - 0.375, P = 0.009). Conclusions The expression of RUNX3 is decreased in pancreatic carcinoma. The expression of CyclinD1 is increased in pancreatic carcinoma. They may play an important role in the carcinogenesis and progression of pancreatic carcinoma.
2.Analysis of Abnormal Use of Anti-tumor Drugs in the Clinic
Jinglin LIU ; Chunnuan WU ; Xiaokun SONG
China Pharmacy 2020;31(7):873-878
OBJECTIVE:To study the abnormal use of anti-tumor dr ugs i n the clinic in order to provide reference for rational use of drugs in the clinic. METHODS :Referring to foreign and domestic anti-tumor drug use guidelines and literatures ,Guidelines for Clinical Use of New Anti-tumor Drugs (2018 edition),Off-label Drug Use List (2019 edition),Practical Oncology (secondary edition),anti-tumor drug package inserts approved by FDA and package inserts of anti-tumor drug listed in China ,abnormal use of antitumor drugs (including instructions ,special indications ,and the order of administration of new anti-tumor drugs ) was summarized and analyzed. RESULTS & CONCLUSIONS :The off-label use of anti-tumor drugs were summarized in this paper , including 11 drug varieties and 4 kinds of off-label drug items ,such as off-label drug use plan (recombinant human endostatin , rituximab),off-label administration route (pemetrexed disodium ,bortezomib,bevacizumab),off-label administration lines (erlotinib,gefitinib),off-label drug dosage (actinomycin D ,gemcitabine,ifosfamide,etoposide). They should be carefully selected and strictly monitored in clinical use ,and treatment plan should be adjusted according to needs. Among the special indications,cyclophosphamide,cytarabine,methotrexate and cisplatin were used in large doses ,which were 2 000-2 400 mg/m2, 2 000 mg/m2,12 g/m2 and 80-120 mg/m2,respectively;individual differences should be paid attention to and therapeutic drug monitoring should be carried out if necessary. In the scheme of combination of new anti-tumor drugs or traditional chemotherapy drugs,there were 5 categories and 11 items in total ,such as combination of molecular targeted anti-tumor drugs with traditional chemotherapy drugs (such as docetaxel at first ,gefitinib at the same time or later ),combination of target immunocheckpoint drugs with traditional chemotherapy drugs (such as platinum at first ,then nivolumab ),and molecular targeted anti-tumor drugs combination(such as pertuzumab and trastuzumab should be given in sequence ,in either order ). In clinical use ,histopathological diagnosis should be made clear , and drugs with specific targets should be used after gene detection and strictly follow the indications.
3.Construction and application evaluation of off-label drug use evaluation system in cancer hospital
Jinglin LIU ; Weiping WANG ; Hongtao WANG ; Ning GAO ; Chao ZHANG ; Xibei ZHOU ; Chunnuan WU ; Lu LU ; Jie ZHANG ; Xiaokun SONG
China Pharmacy 2024;35(17):2082-2087
OBJECTIVE To provide reference for strengthening the standardized management of off-label drug use in cancer hospitals. METHODS The evaluation system for off-label drug use was established to standardize the application, approval, and filing process for off-label drug use in our hospital. The changes in off-label drug application quantity, proportion, disease category and drug category in our hospital were compared before (October 1st, 2021-September 30th, 2022) and after (October 1st, 2022- September 30th, 2023) the establishment of the evaluation system; drug items supported by high-level evidence screened by pharmacy department were analyzed statistically. RESULTS The number of off-label drug use applications in our hospital had gradually increased, from 306 pieces in the fourth quarter of 2021 to 3 828 pieces in the third quarter of 2023. In the year before the construction of the evaluation system, there were a total of 4 482 applications for off-label drug use, and in the year after the construction of the evaluation system, there were 11 840 applications for off-label drug use. After the construction of the evaluation system, the proportion of unregistered off-label drug use significantly decreased, compared to the same period last year (P<0.05). Among them, there were no unregistered applications for off-label drug use for digestive system tumors, head and neck tumors, and radioactive drugs; lymphoma, breast tumors,urogenital system tumors, cytotoxic drugs and new anti-tumor drugs all had a decrease of over 70% in unregistered off-label drug applications. Twenty-seven off-label drug use items related to 19 drugs supported by high-level evidence were screened by the pharmacy department of our hospital, among which 25 items were drug use beyond indication. CONCLUSIONS The establishment of off-label drug use evaluation system in cancer hospital is helpful to the rational use and refined management of clinical anti-tumor drugs.